BlackRock Inc. Acquires Shares of 4,737,519 Inspire Medical Systems, Inc. $INSP

BlackRock Inc. acquired a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 4,737,519 shares of the company’s stock, valued at approximately $211,341,000. BlackRock Inc. owned about 0.16% of Inspire Medical Systems at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Alberta Investment Management Corp bought a new position in Inspire Medical Systems in the 2nd quarter valued at about $5,483,000. Assenagon Asset Management S.A. boosted its stake in Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after purchasing an additional 344,221 shares during the last quarter. Bank of Nova Scotia increased its holdings in Inspire Medical Systems by 49.8% during the 1st quarter. Bank of Nova Scotia now owns 60,000 shares of the company’s stock worth $3,095,000 after purchasing an additional 19,958 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Inspire Medical Systems during the 2nd quarter worth approximately $820,000. Finally, Empowered Funds LLC purchased a new stake in shares of Inspire Medical Systems in the first quarter worth approximately $1,799,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on INSP shares. UBS Group started coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target for the company. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th. Piper Sandler increased their target price on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Wells Fargo & Company dropped their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $66.19.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $60.84 on Friday. The firm has a market cap of $1.76 billion, a PE ratio of 13.17, a P/E/G ratio of 4.70 and a beta of 0.70. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The stock has a fifty day moving average price of $52.73 and a 200-day moving average price of $52.44.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.